Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma

被引:64
作者
Pavey, SJ
Hawson, GAT
Marsh, NA
机构
[1] Queensland Univ Technol, Sch Life Sci, Brisbane, Qld 4001, Australia
[2] Queensland Inst Med Res, Canc Res Unit, Brisbane, Qld 4006, Australia
[3] Redcliffe Hosp, Dept Oncol, Redcliffe, Qld, Australia
关键词
fibrinolysis; plasma fibrinogen; non-small cell lung cancer; survival; prognosis;
D O I
10.1097/00001721-200101000-00008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Comprehensive studies of fibrinolysis in non-small cell lung carcinoma have been limited, and assignment of patients to high/low prognosis groups based on arbitrary cut-offs utilizing fibrinolytic measurements is unstandardized. This study was performed in 166 patients to examine the effects of cut-off values determined in three ways. Model 1 assigned patients to one of three equal groups (low, medium, high) based on fibrinolytic measurements made at diagnosis, Model 2 divided patients into low/high groups using median values, and Model 3 grouped according to the parameter being above/below normal range. In model 1, raised plasma fibrinogen, D-dimer and soluble fibrin were positively associated with poorer survival. In model 2, tissue plasminogen activator antigen was additionally related to poorer prognosis. Model 3 identified seven parameters as significantly related to survival, two not identified by the other models becoming significant [plasmin-antiplasmin, tissue plasminogen activator inhibitor-1 (PAI-1) antigen]. Using multivariate analysis, plasma fibrinogen level was the most uniformly significant parameter. Relative risk estimates indicated that raised plasma fibrinogen, soluble fibrin and D-dimer were associated with increased risk of death. Use of the normal/ above normal cut-off is recommended to provide the maximum number of significant parameters relating to prognosis, and increased plasma D-dimer, PAI-1 antigen and fibrinogen were most closely related to survival/prognosis. Blood Coagul Fibrinolysis 12:51-58 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 20 条
[1]   Haemostatic abnormalities in lung cancer: Prognostic implications [J].
Buccheri, G ;
Ferrigno, D ;
Ginardi, C ;
Zuliani, C .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (01) :50-55
[2]  
GABAZZA EC, 1993, CANCER-AM CANCER SOC, V72, P2134, DOI 10.1002/1097-0142(19931001)72:7<2134::AID-CNCR2820720712>3.0.CO
[3]  
2-8
[4]   EVALUATING PRETHROMBOTIC STATE IN LUNG-CANCER USING MOLECULAR MARKERS [J].
GABAZZA, EC ;
TAGUCHI, O ;
YAMAKAMI, T ;
MACHISHI, M ;
IBATA, H ;
SUZUKI, S .
CHEST, 1993, 103 (01) :196-200
[5]  
GABAZZA EC, 1992, CANCER-AM CANCER SOC, V70, P2631, DOI 10.1002/1097-0142(19921201)70:11<2631::AID-CNCR2820701111>3.0.CO
[6]  
2-9
[7]  
Ishida T, 1991, Nihon Geka Gakkai Zasshi, V92, P1107
[8]   FACTOR IXI-ANTITHROMBIN (IXIAT) AND THROMBIN-ANTITHROMBIN (TAT) COMPLEXES IN LUNG-CANCER PATIENTS [J].
KEMKESMATTHES, B ;
BLEYL, H .
ANNALS OF HEMATOLOGY, 1992, 64 (01) :35-39
[9]  
NAGAYAMA M, 1994, CANCER-AM CANCER SOC, V73, P1398, DOI 10.1002/1097-0142(19940301)73:5<1398::AID-CNCR2820730514>3.0.CO
[10]  
2-9